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Objective. Juvenile dermatomyositis (DM) is a
rare and severe autoimmune condition characterized by
rash and proximal muscle weakness. While some
patients respond to standard treatment, others do not.
This study was carried out to investigate whether histo-
pathologic findings and myositis-specific autoantibodies
(MSAs) have prognostic significance in juvenile DM.
Methods. Muscle biopsy samples (n5 101) from
patients in the UK Juvenile Dermatomyositis Cohort
and Biomarker Study were stained, analyzed, and scored
for severity of histopathologic features. In addition, auto-
antibodies were measured in the serum or plasma of
patients (n5 90) and longitudinal clinical data were col-
lected (median duration of follow-up 4.9 years). Long-
term treatment status (on or off medication over time)
was modeled using generalized estimating equations.
Results. Muscle biopsy scores differed according
to MSA subgroup. When the effects of MSA subgroup
were accounted for, increased severity of muscle histo-
pathologic features was predictive of an increased risk
of remaining on treatment over time: for the global
pathology score (histopathologist’s visual analog scale
[hVAS] score), 1.48-fold higher odds (95% confidence
interval [95% CI] 1.12–1.96; P5 0.0058), and for the
total biopsy score (determined with the standardized
score tool), 1.10-fold higher odds (95% CI 1.01–1.21;
P5 0.038). A protective effect was identified in patients
with anti–Mi-2 autoantibodies, in whom the odds
of remaining on treatment were 7.06-fold lower (95%
CI 1.41–35.36; P5 0.018) despite muscle biopsy scores
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indicating more severe disease. In patients with
anti–nuclear matrix protein 2 autoantibodies, anti–
transcription intermediary factor 1g autoantibodies, or
no detectable autoantibody, increased histopathologic
severity alone, without adjustment for the effect of MSA
subtype, was predictive of the risk of remaining on
treatment: for the hVAS global pathology score, 1.61-
fold higher odds (95% CI 1.16–2.22; P5 0.004), and for
the total biopsy score, 1.13-fold higher odds (95% CI
1.03–1.24; P5 0.013).
Conclusion. Histopathologic severity, in combi-
nation with MSA subtype, is predictive of the risk of
remaining on treatment in patients with juvenile DM
and may be useful for discussing probable treatment
length with parents and patients. Understanding these
associations may identify patients at greater risk of
severe disease.
Accurate prediction of outcomes is a common
problem in rare diseases. For many rare diseases,
including juvenile myositis, patients and clinicians have
an unmet need with regard to the capacity to predict
poor outcomes. A further challenge in the study of rare
autoimmune diseases is that disease mechanisms may
be unknown, which renders biomarker research diffi-
cult. Juvenile dermatomyositis (DM) is an example of a
rare disease in which the disease pathogenesis is only
partially understood. A chronic autoimmune condition
of childhood, juvenile DM is typically characterized by
proximal muscle weakness, elevated levels of muscle
enzymes in the serum, and rashes such as heliotrope
rash and Gottron’s papules (1). Other clinical features
that may contribute to major morbidity include calcino-
sis, ulceration, treatment-resistant rash, and involve-
ment of the gut, lungs, and brain. While some patients
achieve disease remission following a regimen of stan-
dard therapies, others fail to respond. In a recent long-
term study of outcomes in 59 adults who had previously
been diagnosed as having juvenile DM, 51% still had
active disease after a median follow-up of 16 years (2).
At present, early biomarkers of disease that are associ-
ated with long-term outcomes have not been identified.
To facilitate research into the biologic mecha-
nisms, biomarkers, and disease outcomes in juvenile
DM, the UK Juvenile Dermatomyositis Cohort and
Biomarker Study (JDCBS) (n5 506 patients at the time
of this analysis) was established to collect serial clinical
data and biospecimens (3). Such studies open the poten-
tial for the classification of rare diseases into subtypes
that are defined by biomarkers and that are associated
with predictable outcomes, thus allowing investigation
of disease mechanisms that might drive these subtypes.
Biomarker research may eventually enable development
of therapies directed against more relevant targets for
particular subtypes, ultimately leading to better clinical
outcomes. Myositis-specific autoantibodies (MSAs) have
been identified in both adult-onset DM and juvenile DM,
and include anti–Mi-2, anti–melanoma differentiation–
associated gene 5 (anti-MDA5), anti–transcription inter-
mediary factor 1g (anti–TIF-1g, p155/140), and anti–
nuclear matrix protein 2 (anti–NXP-2, p140; also identi-
fied as the anti-MJ autoantibody). Associations between
MSAs and certain clinical features of juvenile DM have
been demonstrated, suggesting that these autoantibodies
may be useful biomarkers (4–11). However, little is
known about the biologic mechanisms underlying differ-
ent MSA subtypes or how they relate to long-term
prognosis.
We have previously developed and validated a
standardized score tool to quantify abnormalities in
muscle tissue obtained by biopsy from patients with
juvenile DM (12,13). Use of immunohistochemistry as a
means of predicting prognosis and informing treatment
is well-established in more prevalent diseases such as
malignancy. Herein, we applied the standardized juve-
nile DM score tool to muscle biopsy samples from a
large cohort of patients with juvenile DM (n5 101) and
tested the hypothesis that early histopathologic score
data contain information predictive of long-term treat-
ment status (on or off medication over time).
PATIENTS AND METHODS
Patients, biopsy material, and clinical data. Pediatric
patients with definite or probable juvenile DM (14) were
recruited to the UK JDCBS (n5 506). Written informed parental
consent and age-appropriate assent were obtained from partici-
pants prior to inclusion in the study. This research was approved
by the UK Northern & Yorkshire Medical Research and Ethics
Committee. Members of the UK Juvenile Dermatomyositis
Research Group (JDRG) are listed in Appendix A. At the time
of this study, muscle biopsy samples from the JDCBS with tissue
of sufficient quantity and quality (n5 101) were analyzed.
All tissue samples were obtained by open quadriceps
biopsy, with the patient placed under general anesthesia. Most of
these patients (94.1%) were treated at Great Ormond Street
Hospital for Children (GOSH), a major referral center, where
the policy is to perform routine biopsy at the time of diagnosis in
patients with juvenile DM. Consequently, a wide range of histo-
pathologic severities, ranging from mild to moderate levels of
severity, is represented in these biopsy samples (see Supplemen-
tary Figures 1A and B, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39753/
abstract). Although the distribution of disease severity scores at
diagnosis was more skewed toward increased severity in those in
whom a muscle biopsy was performed than in those in whom it
was not performed (see Supplementary Table 1 and Supplemen-
tary Figures 1C and D, http://onlinelibrary.wiley.com/doi/10.1002/
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art.39753/abstract), the patients who did not undergo biopsy
were also more likely to have missing data at diagnosis, and
therefore these data are difficult to interpret.
Clinical data collected at the time of diagnosis and time
of muscle biopsy included the physician’s global assessment of
disease activity (score range 0–10, with low scores indicating
minimal disease), Manual Muscle Testing in 8 muscles (score
range 0–80, with high scores indicating no muscle weakness)
(15), Childhood Myositis Assessment Scale (score range 0–52,
with high scores indicating no weakness) (16), and serum
creatine kinase levels (in units/liter). Treatments received by
patients were also recorded at each clinic visit. At the time of
diagnosis, all patients received methotrexate, and the majority
received concomitant steroids, in accordance with international
protocols (17). In patients in whom disease was unresponsive
to treatment with methotrexate, other disease-modifying anti-
rheumatic drugs were administered, including azathioprine,
hydroxychloroquine, intravenous immunoglobulin, and cyclo-
phosphamide. For patients who continued to have refractory
disease, anti–tumor necrosis factor biologic agents (infliximab
or adalimumab) were administered. None of the analyzed
patients were treated with cyclosporin A.
Histologic analyses and scoring of biopsy samples. His-
tologic staining and analysis and scoring of biopsy samples were
conducted as described previously, using the validated juvenile
DM biopsy score tool to calculate a total biopsy score (12,13).
The histopathologist’s visual analog scale (hVAS) global pathol-
ogy score provides a global assessment of the severity of histo-
pathologic features in muscle biopsy tissue. Values for the total
biopsy score (which includes assessment in 4 domains) range
0–27 and those for the hVAS score range 0–10, with higher
scores indicating greater severity.
All histologic assessments and scoring were performed
by a single observer (SAY), who was blinded with regard to the
autoantibody status of each patient with juvenile DM and who
was trained by 2 highly qualified consultant neuropathologists
(TSJ and JLH) who are experienced specialists in the field and
were involved in the development and validation of the juvenile
DM biopsy score tool (12,13). To ensure reliability, scores for
the initial 9 muscle biopsy samples evaluated were cross-
compared to, first, the scores from the 2 trainers, and second,
those generated by an international panel during the validation
of the score tool (13). The intraclass correlation coefficient for
the hVAS score from the observer and those from the interna-
tional panel in the 9 samples was 0.80 (95% confidence interval
[95% CI] 0.62–0.95), indicating high levels of agreement.
Autoantibody screening. Serum or plasma from
patients with juvenile DM were screened for autoantibodies using
immunoprecipitation analyses, as described previously (5,9–11).
Specificity for anti–NXP-2 or anti-MDA5 autoantibodies, visual-
ized as a 140-kd band, was determined by enzyme-linked immu-
nosorbent assay, as described previously (5,11). Since recent
studies in the literature have identified important associations
between the clinical features of juvenile DM and the presence of
MSAs (4–11), and relatively fewer patients with myositis-
associated autoantibodies (MAAs) were present in the biopsy
cohort (with low numbers in individual groups), we elected to
focus on the patient groups in whom the frequencies of MSAs,
i.e., anti–TIF-1g, anti–NXP-2, anti-MDA5, and anti–Mi-2, were
sufficient for these analyses. Patients with MAAs or unidentified
bands were excluded during the statistical analyses of associations
with muscle biopsy scores and associations between muscle biopsy
scores, MSA subtypes, and long-term outcomes. Patients with no
detectable autoantibody were included.
Statistical analysis. Correlations between the total
biopsy score and hVAS score were analyzed using Spearman’s
rank correlation coefficients in R, version 3.2.1 (18). A facto-
rial analysis of variance (ANOVA) was conducted using the
nonparametric Kruskal-Wallis test in R, to identify significant
main effects of MSA subgroups on biopsy scores. Post hoc
comparisons to identify pairs of MSA subgroups whose biopsy
scores significantly differed from each other were performed
using Dunn’s test in the R package dunn.test, with P values
adjusted using the Bonferroni method (19). For each medica-
tion, the distribution of whether that drug was ever received
by patients across each MSA subgroup was analyzed using
Fisher’s exact test in R, with P values adjusted using the
Bonferroni method.
A longitudinal modeling approach, which could
include all available time points for each patient, was adopted
for the analysis of the treatment status outcome, in order
to make maximal use of the available serial clinical data.
A longitudinal approach was preferred over a cross-sectional
approach, which is limited to arbitrarily selected time points of
interest and ignores any other time points. Recurrent event
analysis was preferred over time-to-event analysis, which is
limited to time points up to the first time at which patients
come off treatment and ignores subsequent time points when
patients may come on treatment again.
Longitudinal modeling of long-term treatment status
was performed using generalized estimating equations
(GEEs), a longitudinal method for analyzing recurrent events
that provides more conservative estimates for modeling binary
outcomes than mixed-effects models (20–22). GEE models
were fitted using the R package geepack and an autoregressive
correlation structure (23). Date of diagnosis was considered
the baseline time point. Time from diagnosis was used as the
time variable, which ensured that adjustment was made for the
effects of treatment duration. The no detectable autoantibody
group (n5 20) was the reference category for the MSA vari-
able, to enable more precise estimates, since this group had
the most patients. Although the patients who underwent mus-
cle biopsy are predominantly an inception cohort, a mixture of
patients with incident disease and those with prevalent disease
was recruited when the JDCBS was first started. For this reason,
time from disease onset to diagnosis and time from diagnosis to
biopsy were considered as potential confounders in longitudinal
modeling. Since time from disease onset to diagnosis and time
from diagnosis to biopsy were both found to have significant
effects, these confounders were retained as covariates in subse-
quent analyses. Thus, all parameter estimates are adjusted for
the effects of time from disease onset to diagnosis and time from
diagnosis to biopsy.
Additional potentially confounding variables were
evaluated, and included sex, whether steroids had been
received before biopsy, and ever treatment with cyclophospha-
mide, but none of these had a significant effect in the model,
and therefore these variables were not retained. Estimates of
odds ratios (ORs) are presented as odds of being on treat-
ment, with 95% CIs. Since ORs below 1 can be difficult to
interpret, an OR of ,1 is also presented as the odds of being
off treatment.
2808 DEAKIN ET AL
Parameter estimates from the GEE models were used
to formulate an equation to calculate the odds and, thus, the
predicted probability of being off treatment. To enable pre-
dicted probability to be plotted as a function of the hVAS
score or total biopsy score, a fixed time point of 5 years post-
diagnosis was used. Median values for the time from onset
to diagnosis and time from diagnosis to biopsy were used for
confounding variables. Plots were generated using a custom-
ized R function and the base plotting system.
Bivariate, univariate, and null GEE models were com-
pared using ANOVA for comparison of nested models, and the
R package MuMIn was used for calculation of the quasi–
Akaike’s information criterion (QIC) and the proportion of
weighting for the preferred model using the function
“model.sel()” (24). ANOVA uses a chi-square distribution to
test the likelihood ratios of the models being compared. QIC is
a measure of the relative quality of a GEE model, with lower
values indicating an improved fit. For the comparisons between
the models, the QIC values, proportion of weighting calculated
by model.sel(), chi-square statistics, and P values are reported.
For longitudinal modeling, P values less than 0.05 were
considered statistically significant. Summary statistics are pres-
ented as the median and interquartile range for numeric vari-
ables, and as counts and percentages for categorical variables.
The 95% CIs are presented for all estimated parameters. Fig-
ures depicting correlations and distributions of biopsy scores
and forest plot depictions of the ORs were generated using
GraphPad Prism (version 5.01; GraphPad Software).
RESULTS
Demographic, clinical, and serologic features of
the muscle biopsy cohort. The 101 patients included in
this analysis were predominantly female and white, and
their clinical features indicated a range of disease severities
(Table 1). The MSAs analyzed in this study were detected
in 58.9% of the 90 patients screened, including anti–TIF-
1g in 20.0% of patients, anti–NXP-2 in 16.7% of patients,
anti-MDA5 in 12.2% of patients, and anti–Mi-2 in 5.6% of
patients. MAAs were detected in 10.0% of patients, while
unidentifiable bands were detected in 8.9% of patients
and no autoantibodies were detected in 22.2% of patients.
Differential distribution of muscle biopsy scores
according to autoantibody status. The biopsy hVAS
global pathology scores and total biopsy scores were
highly correlated (R5 0.88, P, 0.0001) (Figure 1C),
which is indicative of the internal consistency of the
standardized tool. Biopsy hVAS scores and total biopsy
scores included both low and high scores and were not
skewed toward either the more severe levels or milder
levels of disease (see Supplementary Figures 1A and B).
Interestingly, there were clear differences in the
distribution of both the hVAS scores and total biopsy
scores between the major MSA subgroups and patients
with no detectable autoantibodies (for the total biopsy
scores, P5 0.0004; for the hVAS scores, P5 0.0005)
(Figures 1A and B). Typically, patients with anti–Mi-2
autoantibodies displayed severe levels of disease, while
those with anti-MDA5 autoantibodies displayed mild dis-
ease. Patients with anti-MDA5 autoantibodies had signifi-
cantly lower hVAS and total biopsy scores compared to all
other groups. Variable levels of histopathologic severity
were observed in patients with anti–NXP-2, those with
anti–TIF-1g, and those with no detectable autoantibody.
Association of muscle biopsy histopathologic
scores with long-term treatment status, and influence
of autoantibody status. We next investigated whether
the MSA subgroups and histopathologic severity were
associated with the long-term outcome of continued treat-
ment over time. Long-term treatment status (on or off
medication over time) was selected as an outcome of clini-
cal importance to both patients and clinicians. Medications
included the immunosuppressive, chemotherapeutic, and
biologic agents detailed in Patients and Methods, and
Table 1. Demographic, clinical, and serologic features of the
cohort of patients who underwent muscle biopsy (n5 101)*
Sex, no. (%)
Male 33 (32.7)
Female 68 (67.3)
Ethnicity, no. (%)
White 72 (71.3)
Black 12 (11.9)
South Asian 8 (7.9)
Other 9 (8.9)
Clinical features at biopsy, median (IQR)†
Age at disease onset, years 6.1 (3.9–9.3)
Physician’s global assessment of
disease activity (scale 0–10)
4.1 (2.0–7.0)
MMT-8 (scale 0–80) 55.0 (40.0–71.5)
CMAS (scale 0–52) 29 (18.75–45)
Creatine kinase, units/liter 213 (55–1,019)
Clinical features at biopsy, median (IQR)
Time from disease onset
to diagnosis, months
2.6 (1.5–7.5)
Time from diagnosis to biopsy, months 0.72 (0.39–0.92)
Biopsy performed .1 month
after diagnosis, no. (%)
17 (16.8)
Taking steroids at biopsy, no. (%)‡ 12 (12.2)
Myositis-specific autoantibodies, no. (%)§ 53 (58.9)
Anti–TIF-1g 18 (20.0)
Anti–NXP-2 15 (16.7)
Anti-MDA5 11 (12.2)
Anti–Mi-2 5 (5.6)
Anti-SRP 2 (2.2)
Anti–PL-7 1 (1.1)
Anti-SAE 1 (1.1)
Myositis-associated autoantibodies, no. (%) 9 (10.0)
Anti–PM-Scl 6 (6.7)
Anti–U1 RNP 2 (2.2)
Anti-topo 1 (1.1)
Unidentified autoantibodies, no. (%) 8 (8.9)
No detectable autoantibodies, no. (%) 20 (22.2)
* IQR5 interquartile range; anti–TIF-1g5 anti–transcription intermedi-
ary factor 1g; anti–NXP-25 anti–nuclear matrix protein 2; anti–MDA55
anti–melanoma differentiation–associated gene 5; anti–SRP5 anti–signal
recognition particle; anti–PL-75 anti–threonyl–transfer RNA synthetase;
anti-SAE5 anti–small ubiquitin-like modifier activating enzyme; anti-
topo5 antitopoisomerase.
† Clinical features were missing for some patients, as follows: for physi-
cian’s global assessment of disease activity, n5 11; for Manual Muscle
Testing in 8 muscles (MMT-8), n5 42; for Childhood Myositis Assess-
ment Scale (CMAS), n5 17; for creatine kinase levels, n5 30.
‡ Steroid use not recorded at the time of biopsy for 3 individuals
(3.0%).
§ Autoantibodies were screened in the serum or plasma of 90 patients
who underwent muscle biopsy. Percentages reflect the number of patients
with a given antibody as a proportion of the total patients tested.
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Figure 1. Distributions and correlations of total biopsy scores and
histopathologist’s visual analog scale (hVAS) global pathology scores in
patients with juvenile dermatomyositis. A and B, The distribution of total
biopsy scores (A) and hVAS scores (B) was determined across sub-
groups of patients with myositis-specific antibodies (MSAs) or no
detectable autoantibody (nil) (n5 69). Factorial analysis of variance
using the Kruskal-Wallis test was performed to analyze the distribution
of these scores. There was a significant main effect of MSA subtype
on the hVAS score (x2 [df4]5 20.0, P5 0.0005; n5 69): for anti–
melanoma differentiation–associated gene 5 (anti-MDA5) vs. anti–Mi-2,
P5 0.0001; for anti-MDA5 vs. anti–nuclear matrix protein 2 (anti–NXP-
2), P5 0.007; for anti-MDA5 vs. anti–transcription intermediary factor
1g (anti–TIF-1g), P5 0.04; for anti-MDA5 vs. no detectable autoanti-
body, P5 0.03. There was also a significant main effect of MSA subtype
on the total biopsy score (x2 [df4]5 20.4, P5 0.0004; n5 69): for anti-
MDA5 vs. anti–Mi-2, P5 0.0009; for anti-MDA5 vs. anti–NXP-2,
P5 0.0006; for anti-MDA5 vs. anti–TIF-1g, P5 0.01; for anti-MDA5 vs.
no detectable autoantibody, P5 0.04. Symbols indicate individual
patients; bars show the median. C, Correlation of total biopsy scores and
hVAS scores was determined by Spearman’s rank correlation analysis
(n5 101) (expressed as R values with 95% confidence intervals).
were not significantly differently distributed across the
MSA subgroups (see Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39753/abstract).
In the GEE models fitted with the MSA sub-
groups and either the hVAS global pathology score or
total biopsy score as covariates, both the hVAS score and
the total biopsy score had a significant effect on long-
term treatment status (Figures 2A and B). In the model
fitted with the hVAS score and MSA subgroup as covari-
ates, a 1-unit increase in the hVAS score was associated
with 1.48-fold higher odds (95% CI 1.12–1.96; P5
0.0058) of being on treatment over time (Figure 2A).
The overall pattern of the GEE model fitted with both
MSA subgroup and the total biopsy score as covariates
was similar to the model fitted with both MSA subgroup
and the hVAS score, although the magnitude of the
effect sizes and statistical significance were smaller
(Figure 2B). A 1-unit increase in the total biopsy score
was associated with 1.10-fold higher odds (95% CI 1.01–
1.21; P5 0.038) of being on treatment over time.
Association of anti–Mi-2 autoantibodies with
higher odds of coming off treatment. Interestingly, the
anti–Mi-2 antibody appeared to have a protective effect in
patients with juvenile DM, with these patients having
7.06-fold lower odds (95% CI 1.41–35.36; P5 0.018) of
remaining on treatment over time. This finding was coun-
terintuitive, since these patients had more severe muscle
disease (as indicated by the total biopsy and hVAS global
pathology scores [Figures 1A and B]). However, this esti-
mate had wide 95% CIs, and therefore the findings war-
rant cautious interpretation. In the model fitted with the
total biopsy score as a covariate, anti–Mi-2 had a protec-
tive effect that was borderline insignificant. In contrast to
those with anti–Mi-2, patients with anti-MDA5 antibodies
displayed a nonsignificant trend toward higher odds of
remaining on treatment over time, despite having less
severe muscle disease at the time of biopsy.
Capacity of muscle histopathologic severity or auto-
antibody subgroup alone to predict prognosis. To exam-
ine whether the biopsy hVAS global pathology score,
total biopsy score, or MSA subgroup alone could be
predictive of long-term treatment status, univariate
GEE models were fitted (Table 2). In these univariate
models, neither the hVAS score nor the total biopsy
score nor any of the MSA subgroups alone had signifi-
cant effects, even though significant effects of these
measures were identified in the bivariate models in
which both muscle histopathologic scores and MSA sub-
types were included.
When the univariate models were compared to
the bivariate models, we found that the bivariate models
were a better fit for the data (Table 3). Therefore, when
all patients with MSAs were assessed, muscle biopsy
scores alone or presence of MSAs alone were not pre-
dictive of prognosis.
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Identifying muscle biopsy scores as a better
prognostic indicator than physician’s global assessment
of disease activity at diagnosis. We also tested whether
substituting the muscle biopsy scores for histopathologic
severity with the physician’s global assessment of disease
activity at diagnosis would result in better prediction of
treatment status. The physician’s global assessment at diag-
nosis did not have a statistically significant effect (Table 2),
and this model was not a better fit than the models with
MSA subgroup and either the hVAS global pathology
score or total biopsy score as covariates (Table 3).
Identifying muscle biopsy scores as a predictor
of long-term treatment status in patients with anti–
NXP-2, patients with anti–TIF-1g, and autoantibody-
negative patients. Given the divergent effects of anti–
Mi-2 and anti-MDA5 in the GEE models fitted with
MSAs and muscle biopsy scores (Figure 2), we reasoned
that taking out these diametrically opposed groups and
removing any potentially overshadowing effects would
enable further analysis of the anti–NXP-2, anti–TIF-1g,
and autoantibody-negative subgroups, which were the
most prevalent subgroups of patients. In this analysis,
muscle biopsy scores alone were associated with long-
term treatment status (Figure 3). A 1-unit increase in
the hVAS global pathology score was associated with
1.61-fold higher odds (95% CI 1.16–2.22; P5 0.004) of
remaining on treatment over time (Figure 3A), while a
1-unit increase in the total biopsy score was associated
with 1.13-fold higher odds (95% CI 1.03–1.24;
P5 0.013) of remaining on treatment over time (Figure
3B). Inclusion of MSAs as a covariate did not improve
the fit (Table 3).
Furthermore, the odds ratio estimates from these
univariate models in which just the patients with anti–
Figure 2. Longitudinal generalized estimating equations (GEE)
modeling of treatment status over time according to MSA subgroups
and hVAS global muscle pathology scores or total biopsy scores.
Forest plots depict odds ratios with 95% confidence intervals for
being on treatment, estimated using GEE models fitted with MSA
subgroups and either hVAS scores (A) or total biopsy scores (B) as
predictors. The no detectable autoantibody group (nil) was used as
the reference category. See Figure 1 for other definitions.
Table 2. Summary of alternative generalized estimating equations
models*
Model, predictor variable
Odds ratio
(95% CI) P
Univariate models (n5 69)
hVAS global pathology score 1.10 (0.92–1.31) 0.28
Total biopsy score 1.03 (0.96–1.10) 0.43
MSAs
No detectable autoantibodies (n5 20) 1.00
Anti-MDA5 (n5 11) 1.69 (0.38–7.60) 0.50
Anti–NXP-2 (n5 16) 1.61 (0.41–6.36) 0.50
Anti–TIF-1g (n5 17) 2.06 (0.46–9.28) 0.35
Anti–Mi-2 (n5 5) 0.68 (0.24–1.90) 0.46
Bivariate model (n5 44)†
Physician’s global assessment of disease
activity at diagnosis (n5 44)
1.27 (0.92–1.76) 0.15
MSAs
No detectable autoantibodies (n5 10) 1.00
Anti-MDA5 (n5 9) 1.56 (0.22–11.00) 0.65
Anti–NXP-2 (n5 9) 0.44 (0.08–2.55) 0.36
Anti–TIF-1g (n5 12) 1.51 (0.20–11.16) 0.69
Anti–Mi-2 (n5 4) 0.78 (0.09–7.00) 0.83
* 95% CI5 95% confidence interval; hVAS5 histopathologist’s visual
analog scale; MSAs5myositis-specific autoantibodies; anti–MDA55
anti–melanoma differentiation–associated gene 5; anti–NXP-25
anti–nuclear matrix protein 2; anti–TIF-1g5 anti–transcription inter-
mediary factor 1g.
† Scores for the physician’s global assessment of disease activity at
diagnosis were available for 44 patients.
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NXP-2, patients with anti–TIF-1g, and autoantibody-
negative patients were considered were similar to those in
the models in which all MSA subgroups were considered
and the effects of MSA subgroup were accounted for (Fig-
ure 2). This indicates that these sets of models are equiva-
lent, and that there is a need to account for the effects of
MSA subgroup when all of the MSA subgroups are con-
sidered in the analyses.
Finally, to facilitate interpretation of these mod-
els, the predicted probability of being off treatment was
plotted as a function of muscle biopsy scores of histo-
pathologic severity at the given time point of 5 years
postdiagnosis (Figures 3C and D). These representa-
tions show that the predicted probability of being off
treatment at 5 years decreases as muscle disease
becomes more severe. For example, a patient with anti–
NXP-2 autoantibodies, anti–TIF-1g autoantibodies, or
no detectable autoantibody and an hVAS global pathol-
ogy score lower than 2 would have a .50% probability
of being off treatment 5 years after the diagnosis. How-
ever, if the hVAS score is higher than 8, the estimated
probability of being off treatment at 5 years after the
diagnosis would be ,6%.
DISCUSSION
The findings of the present study demonstrate
that MSA subgroups are linked to the severity of muscle
Table 3. Summary of model comparisons
ANOVA‡
QIC*
Model selection
weight† x2 P
Bivariate vs. nested univariate and null, for models
fitted with patients with MSAs (n5 69)
Bivariate (hVAS score and MSAs)
Alone 315 – – –
vs. univariate (hVAS score only) 349 1 10.2 (4) 0.038
vs. univariate (MSAs only) 355 1 7.6 (1) 0.0058
vs. null (time only) 350 1 10.5 (5) 0.063
Bivariate (total biopsy score and MSAs)
Alone 336 – – –
vs. univariate (total biopsy score only) 351 0.999 8.6 (4) 0.073
vs. univariate (MSAs only) 355 1 4.3 (1) 0.038
vs. null (time only) 350 0.999 8.6 (5) 0.13
Bivariate (MSAs and PGA) vs. bivariate (MSAs and either
hVAS score or total biopsy score) (n5 44)§
Bivariate (MSAs and PGA)
Alone 316 – – –
vs. bivariate (MSAs and hVAS score) 263 0 – –
vs. bivariate (MSAs and total biopsy score) 293 0 – –
Univariate vs. bivariate and null, for models fitted with
patients with anti–NXP-2, patients with anti–TIF-1g,
and patients with no detectable MSAs (n5 52)¶
Univariate (hVAS score)
Alone 203 – – –
vs. bivariate (hVAS and MSAs) 199 0.85 2.0 (2) 0.36
vs. null (time only) 247 1 8.3 (1) 0.004
Univariate (total biopsy score)
Alone 228 – – –
vs. bivariate (total biopsy score and MSAs) 235 0.96 0.7 (2) 0.71
vs. null (time only) 247 1 6.2 (1) 0.013
* Quasi–Akaike’s information criterion (QIC) is a measurement of the relative quality of the generalized estimating equations
models. Models with lower values indicate a better fit.
† Model selection weight represents the proportion of weight to be given to the bivariate models as compared to their respective
nested univariate model or the model with physician’s global assessment of disease activity at diagnosis (PGA) and myositis-
specific autoantibody (MSA) subgroup, as compared to the models with biopsy score and MSA subgroup, on a scale of 0–1,
when the bivariate, univariate, and null models are compared as indicated. Values of or close to 1 indicate the preferred model.
‡ Analysis of variance (ANOVA) was used to compare the bivariate model to the nested or null models, with results expressed as the chi-
square value (degrees of freedom). The ANOVA tests for a reduction in residual sum of squares, with P values less than 0.05 indicating a sig-
nificantly improved fit for the data.
§ PGA scores at biopsy were available for 44 patients. For the purpose of these model comparisons, the models with MSA sub-
group and histopathologist’s visual analog scale (hVAS) global pathology score or MSA subgroup and total biopsy score were
fitted on the equivalent data set.
¶ Anti–NXP-25 anti–nuclear matrix protein 2; anti–TIF-1g5 anti–transcription intermediary factor 1g.
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disease in juvenile myositis. Furthermore, we show that
MSA subgroups can influence the relationship between
muscle biopsy scores and long-term treatment status in
juvenile DM. Such knowledge may assist in the identifi-
cation of patients who are more likely to respond to
treatment, thus distinguishing them from patients who
are less likely to respond and may need more aggressive
treatment early in the disease.
This is also the first study to identify long-term
clinical patterns in juvenile DM patients with anti–Mi-2
autoantibodies. It is intriguing that the presence of anti–
Mi-2 was associated with a good prognosis despite being
linked to severe muscle disease, and also that there
appeared to be an opposite trend in those with anti-
MDA5. It may be that existing immunosuppressive ther-
apies are more effective against the predominant muscle
involvement that characterizes the disease in patients
with anti–Mi-2 autoantibodies when compared to that
in patients with anti-MDA5, who have more extra-
muscular features. For patients with anti–NXP-2, anti–
TIF-1g, or no detectable autoantibodies, histopatho-
logic severity alone was predictive of the probability of
remaining on treatment over time. Our results suggest
that the treatment response is MSA specific, implying
that the pathophysiologic features in MSA subgroups
are distinct. Therefore, there is a need for further
research and development of therapies that would tar-
get specific pathways identified as aberrant in these
subtypes.
In addition to their usefulness for confirming the
diagnosis, our analysis shows that muscle biopsy scores
contain important information that, in combination with
the MSA status, has prognostic significance. If our
findings are replicated using larger patient numbers,
performance of muscle biopsy as a routine measure dur-
ing the diagnostic examination may be justified in
patients with juvenile DM. Findings of a recent study in
adult patients with DM also suggested that the histo-
pathologic severity varied with MSA subgroups; how-
ever, that study did not include an analysis of MSA
Figure 3. Longitudinal generalized estimating equations (GEE) models of the association between muscle biopsy scores and long-term treat-
ment status (on or off medication over time) in patients with anti–NXP-2 autoantibodies, patients with anti–TIF-1g autoantibodies, and patients
with no detectable autoantibody. A and B, Forest plots depict odds ratios with 95% confidence intervals for being on treatment, estimated using
GEE models fitted with either the hVAS scores (A) or the total biopsy scores (B) as predictors. C and D, The predicted probability of being off
treatment at 5 years postdiagnosis is plotted as a function of either the hVAS scores (C) or the total biopsy scores (D), derived from the GEE
models. Dotted lines represent the 95% confidence intervals. The median values for the time from onset to diagnosis (median 0.214 years) and
for the time from diagnosis to biopsy (median 0.0602 years) were used in the calculations of predicted probabilities. See Figure 1 for other
definitions.
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subgroups and severity of histopathologic features as
they related to outcomes (25). In other fields, such as
breast cancer and glomerulonephritis, histologic analysis
is used to classify a heterogeneous disease into subtypes
to inform optimal treatment regimens (26,27). Such
stratified approaches to medication optimization may
also be applied to rare heterogeneous diseases such as
juvenile DM.
In our analysis, the effect size and statistical sig-
nificance of the hVAS global pathology score were
greater than those of the total biopsy score. Although
this global pathology score correlates well with the stan-
dardized biopsy score, these 2 parts of the biopsy tool
may measure the disease in different ways. The hVAS
score has more flexibility and sensitivity to give weight
to features that affect histopathologic severity, features
that are unaddressed by the specific items within the
score tool. Even though it is based on the individual
histopathologist’s judgment, the hVAS score was found
to have high inter- and intraobserver reliability during
the development and validation of the score tool
(12,13).
Although this study used a large number of
biopsy samples from patients with juvenile DM
(n5 101), the relatively low numbers of patients within
the MSA subgroups limits the precision of the GEE
estimates for associations with specific MSA subgroups,
resulting in wide confidence intervals. For example, the
protective effect identified for anti–Mi-2 was based on
just 5 patients, and the estimate had a wide 95% CI,
although the statistical significance of the association
nonetheless holds.
Low numbers of patients also restricted our abil-
ity to fit more complex models, such as allowing for
interactions between MSA subgroups and muscle biopsy
scores. Because the numbers of patients in the individ-
ual MSA subgroups were low, we consider the most rea-
sonable interpretation of our analysis to be that the
histopathologic severity is predictive of long-term treat-
ment status, and that this effect is influenced by MSA
subgroup. This finding is based on all of the patients
with MSAs analyzed (n5 69). Ideally, these findings
should next be validated in an independent patient
cohort, but at present, there are few centers that rou-
tinely obtain muscle biopsy samples from patients with
juvenile DM, and to our knowledge, this study repre-
sents the largest juvenile DM cohort for which biopsy
data have been linked to autoantibody status and for
which up to 15 years of clinical data have been obtained.
As other juvenile DM cohorts with biopsy data are built
on, it will be important to use these to validate the pres-
ent findings. Low patient numbers is a challenge for any
study of a rare disease, and the knowledge gained from
this study highlights the importance of long-term
biospecimen studies in rare disease cohorts. We also
recognize that our findings cannot be extrapolated
beyond the MSA subgroups analyzed, and further stud-
ies should examine the associations between MAAs and
histopathologic severity in greater numbers of patients.
A second limitation of this study is that the treat-
ment status outcome modeled herein was linked only
indirectly to muscle biopsy scores. Treatment status was
selected as an outcome that would be meaningful to
patients and clinicians, and which could be addressed
using our data set. It also fluctuates less than the other
outcome measures that we have previously considered,
such as “clinically insignificant” disease (28), and thus is
more amenable to fitting complex longitudinal models.
Defining appropriate outcome measures is still an active
area of juvenile DM research, and new measures will
facilitate research into biomarkers and outcomes. Since
not all of the treating clinicians were blinded with regard
to the biopsy and MSA results, it is possible that those
findings could have influenced the treatment practice,
although the relationship between histologic findings,
MSAs, and outcomes is still at the research stage, and
was not known to clinicians at the time that the treat-
ment choices were made.
Although we sought to include as many biopsy
specimens as possible, in practice most of the patients
who underwent muscle biopsy were treated at a single
center (GOSH) and displayed a full range of disease
severity scores at diagnosis. Since a typical overall range
of disease severities is represented, our predictive model
does accommodate a wide range of mild to severe dis-
ease levels. Importantly, a full range of severities of
muscle disease was represented in the cohort analyzed
for histopathologic features in muscle biopsy samples.
However, given that in the UK cohort as a whole, those
patients who underwent a muscle biopsy had, on aver-
age, more severe disease than those who did not
undergo a biopsy, we acknowledge that this skew toward
greater disease severity may limit the generalizability of
our findings, until more centers can generate further
samples that represent the typical distribution of disease
severity and can be obtained from patients with known
autoantibody status and longitudinal data on outcomes.
Nonetheless, our findings are internally valid with
respect to the patients from whom biopsy, MSA status,
and longitudinal outcomes data are available at present.
In summary, we have shown that histopathologic
severity and autoantibody status are correlated with one
another, and that muscle biopsy scores, influenced by
MSA status, are predictive of the probability of
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remaining on treatment in patients with juvenile DM.
Understanding the link between these early biomarkers
of disease and long-term outcomes may give further
insight into different subphenotypes of the disease and
lead to more tailored therapies. Our biomarker-based
modeling strategy may well be applied to adult cohorts
of patients with inflammatory myositis and may also be
a useful approach for the analysis of other rare diseases.
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